Q-omics provides the consensus-scored DUSP23 profile across patient tissues and cancer cell-line models. DUSP23 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DUSP23 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, DUSP23 RNA expression shows 17,941 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where DUSP23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUSP23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUSP23 survival associations across molecular data types. DUSP23 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUSP23 RNA expression–survival associations across cancer types. High DUSP23 expression shows unfavorable associations in ACC, UCS, KIRC, LIHC, KICH and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DUSP23 RNA expression.
This table summarizes DUSP23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for DUSP23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUSP23 shows lower tumor expression in KICH and higher tumor expression in KIRC, KIRP, BLCA, THCA and COAD. The KIRC box plot shows higher DUSP23 RNA expression in tumor versus normal tissue (log2 FC = +1.228, t-test p < 0.001).
This table shows molecular features associated with DUSP23 in patient tissues and cancer cell lines. In patient samples, DUSP23 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DUSP23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
